# MOTS-c Side Effects: What the Research Reports

> MOTS-c side effects from available sources: USADA-documented self-experiment reports, animal-model tolerability data, folate-pathway concerns, and hepatic safety. No Phase 2/3 trial data.

## Reported MOTS-c Side Effects

MOTS-c side effects in published animal studies are limited: rodent tolerability data across multiple studies show no overt toxicity signals at the doses employed [1][2][10][11]. No formal safety endpoint was the primary aim of any published MOTS-c preclinical study.

Human self-experiment adverse events documented by USADA include:
- Palpitations and increased heart rate
- Injection-site irritation and redness
- Insomnia
- Fatigue
- Fever in some reports

These are self-reported events not from controlled studies. Causality has not been established.

## Known Downsides and Safety Signals

**1. Folate-pathway disruption.** MOTS-c inhibits the folate cycle as part of its primary mechanism [1][17]. The folate cycle is essential for DNA synthesis, amino acid metabolism, and one-carbon methylation reactions. Extended inhibition could theoretically impair methylation reactions. No human safety study has characterized this.

**2. WADA S4.4.1 prohibition.** The prohibition exists in part because of potential performance enhancement. The mechanism through which MOTS-c might enhance performance (AMPK activation, improved glucose utilization) is the same mechanism by which it would exert off-target effects.

**3. K14Q variant.** The m.1382A>C polymorphism produces a MOTS-c variant (K14Q) that is a less potent insulin sensitizer and binds CK2alpha at 16-fold lower affinity [9][12]. No study has examined the safety implications of administering wild-type synthetic MOTS-c to K14Q carriers.

## Hepatic Safety

Rodent data show MOTS-c improves hepatic insulin sensitivity and reduces liver fat accumulation in obese models [1][5]. No hepatotoxicity signals appear in published animal studies. No human hepatic safety data are available.

## The Core Safety Uncertainty

The critical limitation of the MOTS-c safety record is the complete absence of human interventional trial data. No Phase 2 or Phase 3 clinical trial safety data for MOTS-c have been published as of 2025. The USADA adverse event reports represent the only available human signal outside of observational endogenous-level studies.

## References

[1] Lee C, et al. Cell Metabolism. 2015;21(3):443-454. DOI: 10.1016/j.cmet.2015.02.009 PMID: 25738459

[2] Reynolds JC, et al. Nature Communications. 2021;12(1):773. DOI: 10.1038/s41467-020-20790-0 PMID: 33473109

[5] Kim SJ, et al. Physiological Reports. 2019;7(13):e14171. DOI: 10.14814/phy2.14171 PMID: 31293078

[9] Zempo H, et al. Aging (Albany NY). 2021;13(2):1801-1817. DOI: 10.18632/aging.202529 PMID: 33468709

[10] Zhong P, et al. JCMM. 2022;26(21):5672-5683. DOI: 10.1111/jcmm.17551 PMID: 36156853

[11] Pham T, et al. Frontiers in Physiology. 2025;16:1602271. DOI: 10.3389/fphys.2025.1602271 PMID: 40661667

[12] Kumagai H, et al. iScience. 2024;27(11):111212. DOI: 10.1016/j.isci.2024.111212 PMID: 39559755

[17] Wan W, et al. J Transl Med. 2023;21(1):36. DOI: 10.1186/s12967-023-03885-2 PMID: 36670507

---

Calibrated from the peer-reviewed record — a machined-instrument digest of the MOTS-c literature, not a clinic, not a vendor, not a prescription.